Toll-like receptor 9 (TLR9) is an innate immune sensor for microbial DNA that erroneously responds to self DNA in autoimmune disease. To prevent autoimmune responses, TLR9 is excluded from the cell surface and silenced until the N-terminal half of the ectodomain (TLR9N) 
Introduction
Toll-like receptors (TLRs) sense a variety of microbial products. Cell surface TLRs, including TLR4/MD-2, TLR1/TLR2, and TLR6/TLR2, recognise microbial membrane lipids, whereas TLR3, TLR7, TLR8, and TLR9 localise to intracellular organelles and recognise microbial nucleic acids [1] [2] [3] . Self/pathogen discrimination by DNA-sensing TLR9 was initially considered to depend on structural differences between self and microbial DNA, such as unmethylated CpG motifs 4 . However, despite its structure-dependent discrimination, TLR9 still has a risk of responding to self DNA 5 .
Self/pathogen discrimination by TLR9 is therefore error-prone and needs to be strengthened by endosomal DNA sensing-based mechanisms.
While self-derived DNA is rapidly degraded by DNase, microbial DNA is resistant to degradation because it is encased in bacterial cell walls or viral particles. Microbial DNA is therefore able to reach endolysosomes and to stimulate TLR9 6 . The aberrant transportation of self DNA to endolysosomes has been shown to exacerbate autoimmunity 5, 7, 8 . In autoimmune diseases such as systemic lupus erythematosus (SLE) or psoriasis, self DNA is complexed with autoantibodies or the cationic antimicrobial peptide LL37. These complexes are resistant to DNase and are delivered into endosomal compartments via FcR-mediated endocytosis, where they are able to activate TLR9, leading to dendritic cell (DC) activation and the production of type I interferon (IFN-I) 7,9,10 .
In addition to ligand transportation, sensor transportation is also tightly controlled to prevent autoimmunity. TLR9 is reported to be localised mostly to the endoplasmic reticulum (ER) and transported to endolysosomes upon activation 11, 12 . If TLR9 is forced to be expressed on the cell surface, TLR9 signals extracellular self DNA, leading to systemic lethal inflammation 13 . TLR9 sequestration from the cell surface is a second mechanism limiting TLR9 activation by self DNA.
A third mechanism depends on the proteolytic cleavage of TLR9 14, 15 . After exiting the ER, the TLR9 ectodomain is cleaved by asparagine endopeptidase (AEP) and/or cathepsins 16, 17 . Truncated TLR9 (TLR9C), but not full-length (TLR9F), recruits
MyD88. The precise role of proteolytic cleavage in DNA sensing is, however, still not clearly understood. TLR9F is able to sense DNA when its expression on the cell surface is forced by a mutation in the transmembrane domain 13 .
Although these mechanisms that restrict TLR9 response to self DNA have been characterised, little is known about the expression, distribution, and processing of endogenous TLR9. In the present study, we investigate these issues with newly established TLR9 monoclonal antibodies (mAbs). TLR9 is unexpectedly detected on the surfaces of splenic DCs but not on bone marrow derived DCs (BM-DCs) or B cells. The TLR9 in DCs is mostly cleaved, but the cleaved N-terminal fragment of the TLR9-ectodomain (TLR9N) remains associated with truncated TLR9 (TLR9C). TLR9C alone fails to sense DNA and requires TLR9N for signalling in response to DNA. These results demonstrate that TLR9N+C is a bona fide DNA sensor.
Results

Establishment of TLR9N-and TLR9C-specific mAbs
To study endogenous TLR9, we established three monoclonal antibodies (mAbs) to mouse TLR9. The specificities of the mAbs were verified by staining membrane permeabilised Ba/F3 cells expressing TLR3, 7, 8, and 9. Anti-mouse TLR9 specifically reacted with mouse TLR9 but did not cross-react with human TLR9 (Fig. 1a) . Because the proteolytic cleavage of the TLR9 ectodomain plays a role in DNA sensing, it was important to determine whether the epitopes for these mAbs were in TLR9N or TLR9C.
We first identified the cleavage sites within TLR9. TLR9-GFP expressed in M12 B cell lymphoma was compared to that in PRAT4A-silenced M12 cells. PRAT4A is a TLR-specific chaperone 18 , and TLR9 fails to exit the ER and therefore remains unprocessed in the absence of PRAT4A. The fragment missing in PRAT4A-silenced M12 cells is therefore likely to be TLR9C (Fig. 1b) . The identified TLR9C fragment was purified, and its N-terminal amino acid sequence was determined. TLR9C was found to start at 461T or 467F (Fig. 1c) . The determined cleavage sites were in the loop region between leucine-rich repeat 14 (LRR14) and LRR15 (Fig. 1d) , consistent with the predictions from previous reports 15, 17 . The presence of two distinct N-terminal fragments of TLR9C might be explained by stepwise processing of TLR9 by asparagine endopeptidase and cathepsins 16 . According to the N-terminal amino acid sequences, a chimeric protein consisting of a signal peptide, N-terminal HA epitope, TLR9
ectodomain, and transmembrane portion was expressed in Ba/F3 cells. Established cells were stained with anti-TLR9 mAb. Two mAbs, J15A7 and B33A4, reacted with TLR9N, whereas another mAb, C34A1, bound to TLR9C (Fig. 1e) . J15A7 bound to TLR9N much less strongly than did B33A4.
TLR9 is expressed on the surface of splenic DCs
TLR9 is believed to be sequestered from the cell surface, but endogenous TLR9 expression on the surface of primary immune cells has never been reported. Using the anti-TLR9 mAb, we next addressed the cell surface expression of TLR9. We first studied overexpressed TLR9 in Ba/F3 cells. As expected, cell surface TLR9 was not detected on TLR9-expressing Ba/F3 cells, although the TLR9 mAbs did detect endosomal TLR9 in membrane permeabilised cells (Fig. 2a) . Unc93B1 transports TLR9
from the ER to endolysosomes 11 . Unc93B1 may also play a role in transporting TLR9
to the cell surface. Unc93B1 was therefore overexpressed in Ba/F3 cells expressing TLR9. Both J15A7 and C34A1, but not the other anti-TLR9N, B33A4, detected cell surface TLR9 (Fig. 2b) . J15A7 also detected cell surface TLR9 on splenic pDCs, CD8α + cDCs, CD4 + cDCs, and double-negative cDCs (Fig. 2c) . The specificity of the J15A7 staining was verified in Tlr9 -/-DCs. Cell surface TLR9 was not detected on splenic DCs from Unc93b1 3d/3d mice harbouring a loss-of-function mutation in the Unc93b1 gene 19 . Taken together with the finding that Unc93B1 overexpression induced the cell surface expression of TLR9 on Ba/F3 cells (Fig. 2b) , these data suggest that
Unc93B1 plays an important role in transporting TLR9 to the cell surface.
In contrast to splenic DCs, BM-pDCs and BM-cDCs did not display easily detectable TLR9 on their cell surfaces (Fig. 2d) . To gain insight into the mechanism controlling the cell surface expression of TLR9 on DCs, BM-cDCs were transduced with retroviral vectors encoding TLR9 or Unc93B1. The overexpression of TLR9, but not Unc93B1, enabled the detection of cell surface TLR9 on BM-cDCs (Fig. 2e) . The co-expression of Unc93B1 weakly enhanced the cell surface expression of TLR9. The cell surface expression of TLR9 was positively correlated with the amount of TLR9. B33A4, an anti-TLR9N mAb, detected endosomal TLR9 but not cell surface TLR9 on BM-cDCs.
Splenic B cells, monocytes, and neutrophils were also stained with the anti-TLR9N mAb J15A7. Cell surface TLR9 was barely detectable on these cells ( Supplementary   Fig. S1 ). TLR9 is reported to be expressed on the apical surface of intestinal epithelial cells (IEC) and to have a role in regulating colonic inflammation 20 . IECs were isolated from the mouse gut, and the cell surface expression of TLR9 on IECs was studied.
TLR9 was undetectable on IECs ( Supplementary Fig. S2 ). In the cells studied, cell surface TLR9 was restricted to splenic DCs.
TLR9N remains associated with TLR9C in endolysosomes
TLR9N is thought to be cleaved off in endolysosomes 14, 16 . Little is known about whether cleaved TLR9N is secreted, degraded, or remains in endosomes. To address this issue, confocal microscopy was used to examine BM-pDCs stained with anti-TLR9N or -TLR9C antibodies. Calnexin staining was used to visualise the ER. Anti-TLR9N detected TLR9 mostly outside the ER, and its staining pattern showed no apparent difference from that of anti-TLR9C (Fig. 3a) . N414 was detected by B33A4, demonstrating that the global structure of TLR9N is not altered by the truncation. J15A7 only weakly detected N414 alone, and the co-expression of TLR9C failed to augment J15A7 staining (Fig. 3e) . To exclude the possibility that J15A7 does not interact with N414 alone, N414 was expressed as a fusion protein, as shown in Fig. 1e , and stained by J15A7. In the context of the fusion, J15A7 interacted with N414 as strongly as it did with N454 ( Supplementary Fig. S4 ).
Further, N414 was expressed in BM-cDCs with or without TLR9C. J15A7 bound to N414 weakly but appreciably, similar to its binding to TLR9N (N466), but the binding was not augmented by TLR9C coexpression (Fig. 3f) . These results strongly suggest that LRR14 is required for the interaction of TLR9N with TLR9C.
TLR9N is required for DNA sensing
The role of TLR9N in TLR9 signalling was then studied. Previous studies have demonstrated that TLR9C alone is able to bind to its ligand and recruit the signalling adaptor MyD88 14, 15 . TLR9F, in contrast, is able to bind to DNA but unable to recruit MyD88 14 . The association of TLR9N with TLR9C led us to examine the role of TLR9N in TLR9C signalling. TLR9 and MyD88 were overexpressed in M12 B cells.
Anti-TLR9N or -TLR9C antibodies were used for immunoprecipitation, and the coprecipitation of MyD88 was examined. Anti-TLR9N and anti-TLR9C both coprecipitated MyD88, and the degree of coprecipitation increased with CpG-B stimulation (Fig. 4a ). MyD88 coprecipitation with anti-TLR9N demonstrated that
MyD88 was recruited to either TLR9F or TLR9N+C. If TLR9F is unable to recruit MyD88 14 , then TLR9N+C is likely to induce signalling in response to DNA. To exclude the involvement of TLR9F, we studied Ba/F3 cells expressing TLR9N, TLR9C, or both.
These cells also expressed a reporter construct that drives the expression of green fluorescent protein (GFP) in response to NF-κB activation. The cells were stimulated with CpG-B, and GFP induction was measured. Ba/F3 cells expressing TLR9C alone failed to reproduce DNA sensing by TLR9C 15 . GFP was induced only when TLR9N
was co-expressed with TLR9C (Fig. 4b) . The requirement for the loop between LRR14
and LRR15 was next investigated using TLR9N truncated at 440 or 454. TLR9 responses were not impaired by TLR9N truncation to 440 (Fig. 4b) . Thus, the loop between LRR14 and LRR15 is not required for TLR9-dependent NF-κB activation. In contrast, TLR9N lacking LRR14 (N414) failed to confer DNA-dependent NF-κB activation in the presence of TLR9C, demonstrating a correlation between TLR9N+C complex formation ( Fig. 3e and 3f ) and TLR9 response.
To further study the responses of TLR9N+C, Tlr9 -/-BM-cDCs were transduced with retroviral vectors encoding TLR9, TLR9N, TLR9C, or TLR9N + TLR9C. TLR9 expression was confirmed by staining membrane-permeabilised cells with the anti-TLR9 mAb (Fig. 5a ). TLR9F and TLR9C were expressed in over 80% of Tlr9 -/-BM-cDCs. The expression of TLR9N+C was estimated based on the TLR9C-dependent augmentation of J15A7 binding to TLR9N. More than 50% of cells were considered J15A7 high . These BM-cDCs were stimulated with lipid A, CpG-A, or CpG-B, and the resulting levels of IL-12p40, TNFα, and IFNβ were determined by ELISA.
Complementation with TLR9N+C was able to induce all the cytokines studied to the same degree observed for TLR9 (Fig. 5b) , demonstrating that TLR9N+C is a DNA-sensing complex.
Discussion
The newly established mAbs to TLR9N or TLR9C have been used to identify TLR9N+C as bona fide DNA-sensing form of TLR9. TLR9 that is overexpressed is reported to be completely cleaved in the phagosome 14 . Here, the majority of endogenous TLR9 in the steady state DCs is shown to be processed and to reside outside the ER. A previous report showed that TLR9N is associated with TLR9C or TLR9F in a macrophage cell line 15 . Consistent with this observation, endogenous TLR9N in BM-cDCs remains associated with TLR9C. Although TLR9C alone is reported to respond to DNA, TLR9C requires TLR9N for DNA sensing. TLR9N+C is primarily responsible for the DNA-dependent TLR9 responses observed in DCs. A previous study using deletion mutations at TLR9N suggested that TLR9N is required for interaction with DNA and subsequent TLR9 activation 24 . In the present study, we employs another approach, a complementation strategy, and similarly concludes that TLR9N is required for TLR9 responses. Even when TLR9N and TLR9C are independently produced in the ER, they are able to self-assemble. TLR9N+C is able to activate an NF-κB reporter in the Ba/F3 cell line and to induce the expression of a variety of cytokines, including TLR ectodomains consist of the tandem repeats of LRM, which is typically 24 amino acids in length 23 . The LRM adopts a loop structure, beginning with a short β-strand coexpression is observed for N440 but not N414, indicating that N414 fails to associate with TLR9C. Therefore, LRR14 is required for the interaction of TLR9N with TLR9C.
Although TLR9N has been reported to be dispensable for the TLR9 response 14, 15 , the present study shows that TLR9N is required for TLR9 responses. It is possible that uncleaved TLR9F is not competent for DNA sensing and that TLR9 proteolytic cleavage activates this activity. Uncleaved TLR9F is, however, reported to be activated in vivo when its expression on the cell surface is forced 13 . These results suggest that TLR9F is able to respond to DNA. The role of proteolytic cleavage in the TLR9 response remains unresolved but can be addressed by comparing TLR9 and TLR9N+C.
Complementation with TLR9 generates both TLR9F and TLR9N+C, whereas complementation with TLR9N + TLR9C generates TLR9N+C only. A comparison of the cytokine production by BM-cDCs complemented with TLR9 and TLR9N + TLR9C reveals no significant differences. Future studies should focus on other cell types, such as B cells and pDCs.
Another mechanism of TLR9 silencing, exclusion from cell surface, is found to be leaky in splenic DCs. Cell surface TLR9 is detected on splenic DCs but not BM-cDCs.
Cell surface TLR9 is detectable on TLR9-overexpressing BM-cDCs but not
Unc93B1-overexpressing cells. In BM-cDCs, TLR9 expression may not be sufficient for its cell surface expression. Considering that the forced expression of TLR9 on the cell surface causes lethal systemic inflammation 13 , cell surface TLR9 expression is likely to be silenced in splenic DCs. The TLR9N mAb J15A7 is able to detect cell surface TLR9 on splenic DCs in normal mice, whereas the other TLR9N mAb, B33A4, is not. Given that B33A4 mAb detects both TLR9F and TLR9N+C in endosomes, the failure of B33A4 mAb to detect cell surface TLR9 is unlikely to be due to the cleavage of the TLR9 ectodomain. Rather, cell surface TLR9 is likely to adopt a conformational state distinct from that of endosomal TLR9. This distinct conformation may be linked to TLR9 silencing on the cell surface. Further studies are needed to characterise the functional difference between cell surface and endosomal TLR9.
Methods
Reagents and Antibodies
Pam 3 CSK 4 was purchased from EMC microcollections. Lipid A Re:595 was purchased from Sigma-Aldrich. CpG-A 1585 (G * G * GGTCAACGTTGAG * G * G * G * G * G; asterisks represent phosphorothioated bases) was synthesised by Hokkaido System Science.
CpG-B 1688 (5′-TCCATGACGTTCCTGATGCT-3′, all phosphorothioated) was synthesised by FASMAC. Recombinant mouse GM-CSF was purchased from R&D Systems. Recombinant murine Flt-3 ligand was purchased from PeproTech. Digitonin was purchased from WAKO and Nacalai. The anti-FLAG antibody and puromycin were purchased from Sigma-Aldrich. G418 was purchased from Nacalai. Anti-HA antibody-conjugated beads and the anti-HA antibody (clone 3F10) were purchased from Roche. The rabbit anti-GFP polyclonal antibody (pAb) used for western blotting was purchased from Invitrogen, and the anti-GFP (FM264) mAb used for immunoprecipitation was previously generated in our laboratory 27 . For immunoprobing TLR9C, a rabbit pAb against the TIR domain was developed in our laboratory. For immunoprobing TLR9N, a rabbit pAb against amino acids 200-300 of mouse TLR9 (# ab13928) was purchased from Abcam.
Plasmid constructs
The C termini of mouse TLR3, 7, 8 and 9, human TLR9, Unc93B1, and Myd88 were tagged with FLAG-6xHis, HA, or GFP epitopes as indicated in the figures. They were generated by PCR and cloned into retroviral pMX, pMXpuro, or pMXneo vectors (kindly provided by Dr Kitamura, Tokyo, Japan). To suppress mouse PRAT4A
expression in M12 cells, we also constructed the shRNA-expressing retroviral vector pSSCH, as described previously 27 . For the constructs encoding TLR9N fragments ( units/ml penicillin, 100 μg/ml streptomycin, 300 μg/ml glutamine, and 50 μM 2-ME.
IL-3 was added to the culture medium for the Ba/F3 cells. The construction of a Ba/F3
line with NF-κB-GFP (BaκB) was described previously 22 .
Retroviral transduction
The pMX, pMXpuro, and pMXneo vectors were transfected into Plat-E packaging cells with FuGene6 (Roche). After 2 days of incubation, supernatants were obtained as virus suspensions. Cells were infected using a mixture of virus suspension and DOTAP (Roche).
Induction of DCs and macrophages from BM cells
BM-cDCs and BM-pDCs were prepared as described previously 22 . Briefly, bone marrow cells were flushed from mouse tibiae and femurs. The RBCs were lysed, and the remaining cells were cultured at 37°C for 1 week in RPMI 1640 medium supplemented with 10% FCS, penicillin-streptomycin-glutamine, and 50 mM 2-ME.
Macrophage, cDC, and pDC differentiation was induced by 100 ng/ml M-CSF, 10 ng/ml GM-CSF, and 50 ng/ml Flt3 ligand, respectively.
Retroviral transduction of BMDCs
Bone marrow (BM) cells from TLR9-deficient mice were cultured with 10 ng/ml of recombinant murine GM-CSF. The retrovirus transduction procedure was repeated on days 5 and 7, and fresh medium was added on the days following each transduction. On day 9, all media, including the retroviruses, were removed; the cells were washed three times; and fresh medium supplemented with GM-CSF was added. On day 10, the BMDCs were harvested and stimulated with TLR ligands.
ELISA
The cytokine and interferon levels in the culture supernatants were measured with ELISA kits (R&D Systems).
TLR9 cleavage site analysis
GFP-tagged mouse TLR9 was stably expressed in M12 cell line. Aliquots of 1×10 10 cells were collected and prepared for immunoprecipitation in lysis buffer (150 mM NaCl, 50 mM Tris·HCl (pH 7.4), 0.5% Triton X-100, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF). Anti-GFP agarose beads (MBL, Japan) were added to the lysate and incubated overnight at 4°C. The beads were collected and washed four times in washing buffer (150 mM NaCl, 30 mM Tris·HCl (pH 7.4), 0.1% Triton X-100), and the precipitated protein was eluted in buffer (150 mM NaCl, 30 mM glycine·HCl (pH 2.5), 0.1% Triton X-100). The eluted sample was dialysed against a new buffer (10 mM NaCl, 0.1% Triton X-100) and concentrated by freeze drying. The concentrated sample was reconstructed in sample buffer (2% SDS, 10% glycerol, 62.5 mM Tris·HCl (pH 6.8), 0.025% bromophenol blue, 5% 2-ME) and subjected to SDS-PAGE. The separated protein was transferred to a PVDF membrane in CAPS transfer buffer. Transferred protein was visualised by Coomassie Blue, and the band corresponding to the C-terminal fragment of TLR9C was cut out. The TLR9C gel band was subjected to N-terminal amino acid analysis, and the amino acid sequence was detected by APRO Science Co., Ltd. (Japan).
Confocal imaging
BM-pDCs were stained with anti-CD11c-Pacific Blue and anti-B220-APC to enable the sorting of CD11c 
Anti-mouse TLR9 monoclonal antibodies
To establish a monoclonal antibody (mAb) against mouse TLR9, BALB/c Tlr9 -/-mice were immunised with Ba/F3 cells expressing mouse TLR9 (Ba/F3_mTLR9). Four days after the final immunisation, splenic cells were fused with SP2/O myeloma cells.
Hybridomas that produced anti-mouse TLR9 mAbs were selected by flow cytometry staining of the Ba/F3 cells used for immunisation. Three mAbs, J15A7 (IgG1/κ), C34A1 (IgG2a/κ), and B33A4 (IgG2a/κ), were isolated and used in the present study.
We used these antibodies at the following concentrations: for cell surface staining: all antibodies, 0.2 µg/ml; for internal staining, J15A7, 0.2 µg/ml, C34A1, 0.075 µg/ml, B33A4, 0.075 µg/ml; for confocal microscopy: all antibodies, 1 µg/ml. 
Cell staining
